BioCentury | Apr 2, 2020
Product Development

Pitt delivers first peer-reviewed data for COVID-19 vaccine, to advance to clinic

In the first peer-reviewed publication for a COVID-19 vaccine headed for the clinic, University of Pittsburgh School of Medicine researchers showed their candidate induced in mice antibody titers thought to be enough for protection. Pitt...
BioCentury | Mar 27, 2020
Regulation

CHMP decisions set stage for approval of Novartis’ SMA gene therapy, Celgene’s Zeposia for MS, Sanofi’s comeback cancer drug

EMA’s CHMP backed conditional approval of an MAA for Zolgensma to treat spinal muscular atrophy in its March set of recommendations, which were made via a virtual meeting because of the COVID-19 outbreak. The agency...
BC Innovations | Dec 12, 2019
Distillery Therapeutics

Combined inhibition of CDK12 and CDK13 for TNBC

DISEASE CATEGORY: Cancer INDICATION: Breast cancer A Moffitt Cancer Center and Research Institute team showed that dual inhibition of CDK12 and CDK13 could treat triple-negative breast cancer (TNBC). In four human TNBC cell lines, an...
BC Innovations | Sep 12, 2019
Distillery Therapeutics

Tumor-targeted serum albumin-chemotherapy conjugates for improved delivery to breast and colorectal cancers

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; colorectal cancer Delivering chemotherapies through conjugation to tumor-targeted albumin could treat breast and colorectal cancers. Albumin is fused with collagen-binding domain of vWF to facilitate attachment to the tumor...
BC Innovations | Aug 22, 2019
Translation in Brief

Systems biology orders strategy to avoid cross-drug resistance in cancer

A Harvard and Mitra Biotech team used systems biology to identify a temporal treatment regimen that uses a glucose metabolism inhibitor to overcome cross-drug resistance in breast cancer. Chemotherapies are often administered in combination regimens...
BC Extra | Aug 17, 2019
Financial News

Aug. 16 Financial Quick Takes: Trio of IPO filings; plus Bellicum, Generex

SpringWorks, Satsuma, Monopar propose IPOs  SpringWorks Therapeutics Inc. (Stamford, Conn.), Satsuma Pharmaceuticals Inc. (South San Francisco, Calif.) and Monopar Therapeutics Inc. (Northbrook, Ill.) are looking to go public on NASDAQ. SpringWorks proposed to raise up...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Innovations | Jun 7, 2019
Translation in Brief

Binding the extracellular matrix to target brain tissue

Attaching biologics to an antigen receptor derived from a fish that preferentially binds the brain's extracellular matrix could enable targeted drug delivery to the CNS. A University of Wisconsin-Madison team found that lamprey-derived immune molecules...
BC Innovations | Jun 4, 2019
Distillery Therapeutics

Targeting brain extracellular matrix to improve doxorubicin efficacy in GBM

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies suggest doxorubicin-loaded nanoparticles targeted to brain extracellular matrix (ECM) could help treat glioblastoma multiforme (GBM). The nanoparticles consist of doxorubicin-loaded liposomes chemically linked to...
BC Extra | May 29, 2019
Company News

CHMP against Emmaus' sickle cell therapy, Taiwan Liposome's doxorubicin

EMA's CHMP issued several opinions Wednesday, including a negative opinion for Emmaus' sickle cell disease therapy, and on re-examination, a negative recommendation for Taiwan Liposome's breast and ovarian cancer treatment. The agency recommended against approval...
Items per page:
1 - 10 of 1361